mdlinx mdlinx
Latest (177) Full Text Articles (6313) Focus on Hematology Article Summary

Changes of Treg and Th17 cells balance in the development of acute and chronic hepatitis B virus infection Full Text
BMC Gastroenterology,  Clinical Article

Xue–Song L et al. – T (Treg) cells and interlukin–17–producing T help cells (Th17) cells are involved in acute and chronic hepatitis B virus (HBV) infection, especially in acute HBV infection (AHB) and acute–on–chronic HBV–related liver failure (ACHBLF). chronic hepatitis B patients (CHB) and ACHBLF patients manifested obvious Treg/Th17 ratio imbalance, which might be linked to disease progression and the continuous HBV infection.

Methods
  • Ten patients with acute HBV infection (AHB) and forty–eight patients with chronic HBV infection, including 12 asymptomatic HBV carriers (HBV carriers), 18 chronic hepatitis B patients (CHB) and 18 acute–on–chronic HBV–related liver failure (ACHBLF) were enrolled.
  • Treg and Th17 cells differentiation related cytokine levels were detected by using ELISA.
  • Flow cytometry was employed to count the Treg and Th17 frequency in peripheral blood.

Results
  • Compared to health controls both AHB and ACHBLF patients favoured Th17 cell differentiation, accompanied by a higher proportion of peripheral Th17 cells (P < 0.01) and high level of interleukin–17A (IL–17A) (P < 0.01).
  • However, asymptomatic HBV carriers and CHB were conducive to Treg cell differentiation.
  • In AHB and ACHBLF, peripheral blood IL–17A + CD4 + T cell frequency increased significantly compared with healthy controls.
  • Changes of Treg and Th17 cell frequency were not completely consistent.
  • Both CHB and ACHBLF had lower level of Treg/Th17 ratio than in health control (P < 0.05).
  • Both plasm IL–17A levels (r = 0.72, p<0.001) and Th17 frequency(r = 0.49, p = 0.0003) negatively correlated with plasma HBV DNA load in patients with chronic HBV infection.
  • In addition, both Th17 frequency and plasm IL–17A levels positively correlated with ALT (r = 0.33,p = 0.01 Vs r = 0.29,p = 0.04) and total bilirubin levels (r = 0.72,p<0.0001 Vs r = 0.53,p = 0.0001) in these chronic HBV–infected subjects.
  • However, for AHB there were positive correlation between both Th17 frequency (r = 0.64, p = 0.04) and plasm IL–17A levels (r = 0.69, p = 0.02) with serum ALT levels, but no significant correlation between both HBV DNA level and total bilirubin level with Th17 frequency or plasm IL–17A levels were found.
  • Furthermore, Treg/Th17 ratio was negatively correlated with total bilirubin levels (r = 0.41, p = 0.004) in chronic HBV–infected patients, especially in patients with ACHBLF (r = 0.69,p = 0.001) and positively correlated with viral load in these chronic HBV–infected subjects (r = 0.55, p<0.0001).

► Click here to access Full Text, PubMed, Publisher and related articles...
<< Previous Article | Next Article >>

Your Unread Messages in Oncology

See All >> Messages include industry-sponsored communications and special communications from MDLinx

Most Popular Oncology Articles

Last month's top read Top Articles of 2012

1 Intensive chemotherapy and immunotherapy in patients with newly diagnosed primary CNS lymphoma: CALGB 50202 (Alliance 50202) Journal of Clinical Oncology, April 15, 2013    Clinical Article

2 Neoadjuvant chemotherapy with or without zoledronic acid in early breast cancer: a randomized biomarker pilot study Clinical Cancer Research, May 6, 2013    Clinical Article

3 Mortality after radical prostatectomy or external beam radiotherapy for localized prostate cancer Journal of the National Cancer Institute, May 1, 2013    Clinical Article

4 Estimated risk of cardiovascular disease and secondary cancers with modern highly conformal radiotherapy for early-stage mediastinal Hodgkin lymphoma Annals of Oncology, May 6, 2013    Clinical Article

5 Rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisolone in patients with newly diagnosed diffuse large B-cell non-Hodgkin lymphoma: a phase 3 comparison of dose intensification with 14-day versus 21-day cycles The Lancet, April 23, 2013    Clinical Article

6 Efficacy and safety of 12-weekly versus 4-weekly zoledronic acid for prolonged treatment of patients with bone metastases from breast cancer (ZOOM): a phase 3, open-label, randomised, non-inferiority trial The Lancet Oncology, May 17, 2013    Clinical Article

7 Dose-dense rituximab-CHOP compared with standard rituximab-CHOP in elderly patients with diffuse large B-cell lymphoma (the LNH03-6B study): a randomised phase 3 trial The Lancet Oncology, May 3, 2013    Clinical Article

8 Association of metformin use with cancer incidence and mortality: A meta-analysis Cancer Epidemiology, April 22, 2013    Review Article

9 Radiotherapy or tamoxifen after conserving surgery for breast cancers of excellent prognosis: British Association of Surgical Oncology (BASO) II trial European Journal of Cancer, April 2, 2013    Clinical Article

10 Capecitabine and cisplatin with or without cetuximab for patients with previously untreated advanced gastric cancer (EXPAND): a randomised, open-label phase 3 trial The Lancet Oncology, May 3, 2013    Clinical Article

11 Analysis in early stage triple-negative breast cancer treated with mastectomy without adjuvant radiotherapy: Patterns of failure and prognostic factors Cancer, April 12, 2013    Clinical Article

12 Magnitude of trastuzumab benefit in patients with HER2-positive, invasive lobular breast carcinoma: Results from the HERA Trial Journal of Clinical Oncology, April 25, 2013    Clinical Article

13 Thalidomide versus active supportive care for maintenance in patients with malignant mesothelioma after first-line chemotherapy (NVALT 5): an open-label, multicentre, randomised phase 3 study The Lancet Oncology, May 3, 2013    Clinical Article

14 AVEREL: A randomized phase III trial evaluating bevacizumab in combination with docetaxel and trastuzumab as first-line therapy for HER2-positive locally recurrent/metastatic breast cancer Journal of Clinical Oncology, April 15, 2013    Clinical Article

15 Survival of pediatric patients after relapsed osteosarcoma: The St. Jude Childrens Research Hospital experience Cancer, May 2, 2013

16 Specific adverse events predict survival benefit in patients treated with tamoxifen or aromatase inhibitors: An International Tamoxifen Exemestane Adjuvant Multinational Trial analysis Journal of Clinical Oncology, April 30, 2013    Clinical Article

17 Combination neratinib (HKI-272) and paclitaxel therapy in patients with HER2-positive metastatic breast cancer British Journal of Cancer, May 7, 2013    Clinical Article

18 Impact of EGFR Inhibitor in Non-Small Cell Lung Cancer on Progression-Free and Overall Survival: A Meta-Analysis Journal of the National Cancer Institute, April 19, 2013    Evidence Based Medicine

19 Prognosis of women with primary breast cancer diagnosed during pregnancy: results from an international collaborative study Journal of Clinical Oncology, April 29, 2013    Clinical Article

20 Capecitabine and cisplatin with or without cetuximab for patients with previously untreated advanced gastric cancer (EXPAND): a randomised, open-label phase 3 trial The Lancet Oncology, April 23, 2013    Clinical Article

Indexed Journals in Oncology: Journal of Clinical Oncology, Cancer Research, Annals Oncologymore

Other Topics in Oncology

Register now to view all the MDLinx contents (FREE)!

  • Stay current on the latest literature, research and clinical news
  • Get special communications and offers from MDLinx and our sponsors
  • Receive invitations to paid market research
View Samples and Register

Stay current - Media Tool

Newsletter
RSS
Follow Us
Facebook

Receive free subspecialty
"5-minute updates" via email

Sign up!

Send the E-mail Newsletter to a Colleague


Send

Subscribe to our free RSS feeds:
Get the latest news in your specialty automatically added to your newsreader or your personal My Yahoo!, Google, My MSN or My AOL page. Learn More

Follow Us on Twitter
Twitter is a rich source of instantly updated information. Join today and follow @MDLinx to start receiving tweets. Learn More

Close